BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Leader A, Hofstetter L, Spectre G. Challenges and Advances in Managing Thrombocytopenic Cancer Patients. J Clin Med 2021;10:1169. [PMID: 33799591 DOI: 10.3390/jcm10061169] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Yildirim ÖA, Erdur E. Pancreatic cancer treatment after FOLFIRINOX: prognostic importance of chemotherapy dose intensity and albumin/globulin ratio in second line. Journal of Health Sciences and Medicine 2022;5:156-60. [DOI: 10.32322/jhsm.1011658] [Reference Citation Analysis]
2 Wilkins CR, Ortiz J, Gilbert LJ, Yin S, Mones JV, Parameswaran R, Mantha S, Soff GA. Romiplostim for chemotherapy‐induced thrombocytopenia: Efficacy and safety of extended use. Res Pract Thromb Haemost 2022;6. [DOI: 10.1002/rth2.12701] [Reference Citation Analysis]
3 Ten Cate H, Lämmle B. Special Issue: "The Latest Clinical Advances in Thrombocytopenia". J Clin Med 2021;10:3463. [PMID: 34441759 DOI: 10.3390/jcm10163463] [Reference Citation Analysis]
4 Song AB, Goodarzi K, Karp Leaf R, Kuter DJ, Al-Samkari H. Thrombopoietin level predicts response to treatment with romiplostim in chemotherapy-induced thrombocytopenia. Am J Hematol 2021;96:1563-8. [PMID: 34453757 DOI: 10.1002/ajh.26338] [Reference Citation Analysis]